Recombinant bacillus Calmette-Guerin as a potential vector for preventive HIV type 1 vaccines

AIDS Research and Human Retroviruses

Volumn 16, Issue 2, 2000, Pages 91-98

  Falk, L A ^a   Goldenthal, K L ^a   Esparza, J ^b   Aguado, M T ^c   Osmanov, S ^b   Ballou, W R ^d  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b UNAIDS   (Switzerland)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d Department of Immunology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RESEARCH; FEASIBILITY STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

EID: 84941944737     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200309421     Document Type: Conference Paper

References (46)

1. 1. Honda M, Matsuo K, Nakasone T, Okamoto Y, Yoshizaki H, Kitamura K, Sugiura W, Watanabe K, Fukushima Y, Haga S, Katsura Y, Tasaka H, Komuro K, Yamada T, Asano T, Yamaskai A, and Yamazaki S: Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guerin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc Natl Acad Sci USA 1995;92:10693-10697.
2. 2. Hanson MS, Bansal GP, Langermann S, Stover CK, and Orme I: Efficacy and safety of live recombinant BCG vaccines. Dev Biol Stand 1995;84:229-236.
3. 3. Gicquel B: BCG as a vector for the construction of multivalent recombinant vaccines. Biologicals 1995;23:113-118.
4. 4. Flynn JL: Recombinant BCG as an antigen delivery system. Cell Mol Biol 1994;40(Suppl. 1):31-36.
5. 5. Kameoka M, Nishino Y, Matsuo K, Ohara N, Kimura T, Yamazaki T, and Ikuta K: Cytotoxic T lymphocytes response in mice induced by a recombinant BCG vaccination which produces an extracellular alpha antigen that fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop. Vaccine 1994;12:153-158.
6. 6. Yasutomi Y, Koenig S, Haun SS, Stover K, Jackson RK, Conrad P, Conley AJ, Emini EA, Fuerst TR, and Letvin NL: Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. J Immunol 1993;150:3101-3107.
7. 7. Lim EM, Lagranderie L, Le Grand R, Rauzier J, Gherorghiu M, Gicquel B, and Winter N: Recombinant Mycobacterium bovis BCG producing the N-terminal half of SIVmac251 env antigen induces neutralizing antibodies and cytotoxic lymphocyte responses in mice and guinea pigs. AIDS Res Hum Retroviruses 1997;13:1573-1581.
8. 8. Winter N, Lagranderie M, Gangloff S, Leclerc C, Gheorghiu M, and Gicquel B: Recombinant BCG strains expressing the SIVmac251nef gene induce proliferative and CTL responses against nef synthetic peptides in mice. Vaccine 1995;13:471-478.
9. 9. Lu Y: HIV-1 vaccine candidate evaluation in non-human primates. Crit Rev Oncog 1997;8:273-291.
10. 10. Honda M, Amy Y, Kenji S, Ando S, Matsuo K, Lu Y, and Yamasaki S: Recombinant BCG vector-based vaccine trial to SHIV challenge. In: Program Book of 8th Annual Meeting of NCVDG for AIDS, 1996, p. 184.
11. 11. Beddows S. Imperial School of Medicine at St. Mary's, London, UK, unpublished data.
12. 12. US Code of Federal Regulations. 1997. Title 21, parts 610.11 and 610.14, Washington, DC, US Government Printing Office.
13. 13. Center for Biologies Evaluation and Research, US Food and Drug Administration: Guidance for Industry for the evaluation of combination vaccines for preventable disease: Production, testing and clinical studies (April 1997). Federal Register 1997;62: 17624-17625.
14. 14. Brennan MJ, Collins FM, and Morris SL: Propelling novel vaccines directed against tuberculosis through the regulatory process. Tubercle Lung Dis 1999;79:145-151.
15. 15. Hoft DF, Brown RM, and Roodman ST: Bacille Calmette-Guerin vaccination enhances human gamma delta T cell responsiveness to mycobacteria suggestive of a memory-like phenotype. J Immunol 1998;161:1045-1054.
16. 16. Kemp EB, Belshe RB, and Hoft DF: Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guerin. J Infect Dis 1996;174:113-119.
17. 17. Colston MJ: The cellular and molecular basis of immunity against mycobacterial diseases. J Appl Bacteriol 1996;81:33S-39S.
18. 18. Gheorghiu M, Langranderie MRR, Gicquel B, and Leclerc C: Mycobacterium bovis BCG priming induces a strong potentiation of the antibody response induced by recombinant BCG expressing a foreign antigen. Infect Immun 1994;62:4287-4295.
19. 19. Lagranderie M, Murray A, Gicquel B, Leclerc C, and Gheorghiu M: Oral immunization with recombinant BCG induces cellular and humoral immune responses against the foreign antigen. Vaccine 1993;11:1283-1290.
20. 20. Stover CK, Bansal GP, Hanson MS, Burlein JE, Palaszynski SR, Young JF, Koenig S, Young DB, Sadziene A, and Barbour AG: Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: A candidate Lyme disease vaccine. J Exp Med 1993; 178:197-209.
21. 21. Stover CK, Bansal GP, Langerman S, and Hanson MS: Protective immunity elicited by rBCG vaccines. Dev Biol Stand 1994;82: 163-170.
22. 22. Guleria I, Teitelbaum R, McAdam RA, Kalpana G, Jacobs WR, and Bloom BR: Auxotrophic vaccines for tuberculosis. Nat Med 1996;2:334-337.
23. 23. Koup RA, Safrit JF, Cao Y, Andrews A, McLeod G, Borkowski W, Farthing C, and Ho DD: Temporal association of cellular immune response with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68: 4650-4655.
24. 24. Borrow P, Lewicki H, Hahn BH, Shaw GM, and Oldstone MBA: Virus-specific CD8+ cytotoxic T lymphocyte activity associated with control viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-6110.
25. 25. Rinaldo C, Huang X-L, Fan Z, Ding M, Beltz L, Logar A, Panicali D, Mazzara G, Liebmann J, Cottrill M, and Gupta P: High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term non-progressors. J Virol 1995;69:5838-5842.
26. 26. Harrer T, Harrer E, Kalamas SA, Elbeik T, Stapranas SI, Feinberg MB, Cao Y, Ho DD, Yilma T, Caliendo AM, Johnson RP, Buchbinder SP, and Walker BD: Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infections. AIDS Res Hum Retroviruses 1996;12:585-592.
27. 27. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, Whitby D, Sabally S, Gallimore A, Corrah T, Takiguchi M. Schultz T, McMichael A, and Whittle JH: HIV-specific cytotoxic T cells in HIV-exposed but uninfected Gambian woman. Nat Med 1995;1:59-64.
28. 28. Rowland-Jones SL, Nixon DF, Aldhous MC, Gotch F, Ariyoshi K, Hallam N, Kroll JS, Froebel K, and McMichael A: HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 1993;341:860-861.
29. 29. Wilson SE, Pedersen SL, Kunich JC, Wilkins VK, Mann DL, Mazzara GP, Tartaglia J, Celum CL, and Sheppard HW: Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte response in early HIV type 1 clade B infection. AIDS Res Hum Retroviruses 1998;14:925-937.
30. 30. Ferrari G, Humphrey W, McElrath MJ, Excler J-L, Duliege A-M, Clements ML, Corey LC, Bolegnesi DP, and Weinhold KJ: Clade B-based HIV-1 vaccines elicitcross-clade cytotoxic T lymphocytes reactivities in uninfected volunteers. Proc Natl Acad Sci USA 1997;94:1396-1401.
31. 31. Lynch JA, deSouza M, Robb MD, Markowitz L, Nitayaphan S, Sapan CV, Mann DL, Birx DL, and Cox JH: Cross-clade cytotoxic T cell response to HIV-1 proteins among HLA disparate North Americans and Thais. J Infect Dis 1998;178:1040-1046.
32. 32. Cao H, Kanki P, Sankale J-L, Dieng-Starr A, Mazzara GP, Kalams SA, Korber B, Mboup S, and Walker BD: Cytotoxic T-lymphocytes cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development. J Virol 1997;71:8615-8623.
33. 33. Goulder PJ, Sewell AK, Lalloo DG, Price DA, Whelan JA, Evans J, Taylor JA, Luzzi G, Giangrande P, Phillips RE, and McMichaels AJZ: Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. J Exp Med 1997;185:1423-1433.
34. 34. McMichaels AJ and Phillips RE: Escape of human immunodeficiency virus from immune control. Annu Rev Immunol 1997;15: 271-296.
35. 35. Ferrari G: Unpublished data, Duke University Medical Center, Durham, NC.
36. 36. Hoft D: Unpublished data, St. Louis University Health Science Center, MO.
37. 37. Falk LF, Midthun K, McVittie LD, and Goldenthal KL: Testing and licensure of combination vaccines for the prevention of infectious diseases. In: Combination Vaccines: Development, Clinical Research and Approval (Ellis RW, ed.). Humana Press, Totowa, NJ, 1999, pp. 233-248.
38. 38. Falk LA, Chandler DKF, and Richman P: Review of current pre-clinical testing strategies for bacterial vaccines. Dev Biol Stand 1998;95:25-29.
39. 39. Griffen JFT, Makintosh CG, and Buchan GS: Animal models of protective immunity in tuberculosis to evaluate candidate vaccines. Trends Microbiol 1995;3:418-424.
40. 40. Clements-Mann ML: Lessons for AIDS vaccine development from non-AIDS vaccines. AIDS Res Hum Retroviruses 1998;14(Suppl. 3):S 197-203.
41. 41. Goldenthal KL, Vaillancourt JM, Geber A, and Lucey DR: Preventive HIV type 1 vaccine clinical trials: A regulatory perspective. AIDS Res Hum Retroviruses 1998;14(Suppl. 3):S333-340.
42. 42. Collins FM: Mycobacterial pathogenesis: A historical perspective. Frontiers Biosci 1998;3:123-132.
43. 43. Fine PE, Ponnighaus JM, and Maine NP: The relationship between delayed type hypersensitivity and protective immunity induced by mycobacterial vaccines in man. Lepr Rev 1986;57(Suppl. 2): 275-283.
44. 44. Besnard M, Sauvion S, Offredo C, Gaudelus J, Gaillard J-L, Veber F, and Blanche S: Bacillus Calmette-Guerin infection after vaccination of human immunodeficiency virus-infected children. Pediatr Infect Dis J 1993;12:993-997.
45. 45. Rosenfeldt V, Paerregaard A, and Valerius NH: Disseminated infection with bacillus Calmette-Guerin in a child with advanced HIV disease. Scand J Infect Dis 1997;29:526-527.
46. 46. O'Brien KL, Ruff AJ, Louis MA, Desormeaux J, Joseph DJ, McBrian M, Coberly J, Boulos R, and Halsey NA: Bacillus Calmette-Guerin complications in children born to HIV-1-infected women with a review of the literature. Pediatrics 1995;95:414-418.